/
KOD
$37.74+$1.80 (+5.01%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
63M shares
52-week range
$3.60 – $47.84
77% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-55.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $490.0K | $911.0K | $4.2M | $8.7M | $11.0M | $25.9M | $26.7M | $0 |
| Gross profit | −$490.0K | −$911.0K | −$4.2M | −$8.7M | −$11.0M | −$25.9M | −$26.7M | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $18.8M | $37.5M | $107.4M | $217.3M | $267.6M | $206.3M | $126.1M | $182.4M |
| Operating income | −$26.4M | −$49.2M | −$136.0M | −$267.1M | −$341.4M | −$277.3M | −$186.8M | −$234.4M |
| EBITDA | −$35.4M | −$46.4M | −$128.9M | −$258.3M | −$322.8M | −$234.5M | −$149.5M | −$203.6M |
| Net income | −$41.4M | −$47.4M | −$133.1M | −$267.0M | −$333.8M | −$260.5M | −$176.2M | −$230.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.16 | -1.23 | -2.91 | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-3.74 | $-4.16–$-3.35 | 5 |
| 2027 | $46M | $-3.12 | $-3.53–$-2.72 | 4 |
| 2028 | $236M | $-0.86 | $-1.74–$-0.39 | 3 |
| 2029 | $498M | $1.17 | $0.26–$1.84 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.74
Price
$37.74
Implied downside
-98%
Peer comparison
Kodiak Sciences Inc Common Stock
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
www.kodiak.com- Employees
- 124
- IPO / List date
- Oct 4, 2018
- HQ
- PALO ALTO, CA
Held by traders on TradeandTell
No one on the platform currently holds KOD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 294,300 | $11.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KOD yet.
